Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

39 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Clinical pharmacokinetics and pharmacodynamics of inhaled insulin.
Patton JS, Bukar JG, Eldon MA. Patton JS, et al. Among authors: eldon ma. Clin Pharmacokinet. 2004;43(12):781-801. doi: 10.2165/00003088-200443120-00002. Clin Pharmacokinet. 2004. PMID: 15355125 Review.
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.
Charych D, Khalili S, Dixit V, Kirk P, Chang T, Langowski J, Rubas W, Doberstein SK, Eldon M, Hoch U, Zalevsky J. Charych D, et al. Among authors: eldon m. PLoS One. 2017 Jul 5;12(7):e0179431. doi: 10.1371/journal.pone.0179431. eCollection 2017. PLoS One. 2017. PMID: 28678791 Free PMC article.
Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease.
Aweeka FT, Gottwald MD, Gambertoglio JG, Wright TL, Boyer TD, Pollock AS, Eldon MA, Kugler AR, Alldredge BK. Aweeka FT, et al. Among authors: eldon ma. Epilepsia. 1999 Jun;40(6):777-82. doi: 10.1111/j.1528-1157.1999.tb00778.x. Epilepsia. 1999. PMID: 10368078 Clinical Trial.
Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration.
Sy SK, Sweeney TD, Ji C, Hoch U, Eldon MA. Sy SK, et al. Among authors: eldon ma. Cancer Chemother Pharmacol. 2017 Jan;79(1):57-67. doi: 10.1007/s00280-016-3192-6. Epub 2016 Nov 30. Cancer Chemother Pharmacol. 2017. PMID: 27904955 Free PMC article.
Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder.
Duddu SP, Sisk SA, Walter YH, Tarara TE, Trimble KR, Clark AR, Eldon MA, Elton RC, Pickford M, Hirst PH, Newman SP, Weers JG. Duddu SP, et al. Among authors: eldon ma. Pharm Res. 2002 May;19(5):689-95. doi: 10.1023/a:1015322616613. Pharm Res. 2002. PMID: 12069174 Clinical Trial.
Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients.
Burkart GJ, Smaldone GC, Eldon MA, Venkataramanan R, Dauber J, Zeevi A, McCurry K, McKaveney TP, Corcoran TE, Griffith BP, Iacono AT. Burkart GJ, et al. Among authors: eldon ma. Pharm Res. 2003 Feb;20(2):252-6. doi: 10.1023/a:1022275222207. Pharm Res. 2003. PMID: 12636164
Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending-dose study.
Eldon MA, Kugler AR, Medve RA, Bui K, Butler K, Sostek M. Eldon MA, et al. Clin Pharmacol Drug Dev. 2015 Nov;4(6):434-41. doi: 10.1002/cpdd.206. Epub 2015 Sep 4. Clin Pharmacol Drug Dev. 2015. PMID: 27137715 Clinical Trial.
Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.
Sy SKB, Chia YL, Gordi T, Hoch U, Eldon MA. Sy SKB, et al. Among authors: eldon ma. Cancer Chemother Pharmacol. 2018 May;81(5):897-909. doi: 10.1007/s00280-018-3562-3. Epub 2018 Mar 21. Cancer Chemother Pharmacol. 2018. PMID: 29564497 Free PMC article.
Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol.
Eldon MA, Kugler AR, Medve RA, Bui K, Butler K, Sostek M. Eldon MA, et al. Clin Pharmacol Drug Dev. 2015 Nov;4(6):442-8. doi: 10.1002/cpdd.204. Epub 2015 Sep 4. Clin Pharmacol Drug Dev. 2015. PMID: 27137716 Clinical Trial.
Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.
Hoch U, Staschen CM, Johnson RK, Eldon MA. Hoch U, et al. Among authors: eldon ma. Cancer Chemother Pharmacol. 2014 Dec;74(6):1125-37. doi: 10.1007/s00280-014-2577-7. Epub 2014 Sep 17. Cancer Chemother Pharmacol. 2014. PMID: 25228368 Free PMC article.
39 results
Jump to page
Feedback